USA – Neuralink, the brain-computer interface (BCI) startup founded by Elon Musk, has announced the launch of a new feasibility study called CONVOY.
Approved by regulatory authorities, this study will explore the use of Neuralink’s wireless N1 implant to control an investigational assistive robotic arm.
The announcement, made on X (formerly Twitter), highlighted the company’s vision for advancing physical and digital freedom for individuals with mobility challenges.
“This is an important first step towards restoring not only digital freedom but also physical freedom,” Neuralink shared.
The company further explained that the CONVOY study would allow participants from its ongoing PRIME Study to cross-enroll, expanding the scope of its research.
Understanding Neuralink’s BCI technology
The PRIME Study (Precise Robotically Implanted Brain-Computer Interface) involves the implantation of Neuralink’s N1 device into regions of the brain responsible for movement planning.
This small, cosmetically hidden device is designed to interpret neural signals, enabling users to control digital devices such as computers and smartphones simply by intending to move.
The ongoing clinical trial primarily focuses on individuals with quadriplegia, aiming to provide them with the ability to operate digital devices using their thoughts.
Neuralink continues to recruit participants for the study, which has already demonstrated promising results.
In February, 29-year-old quadriplegic participant Noland Arbaugh became the first recipient of Neuralink’s BCI device.
Following the procedure, Arbaugh gained the ability to play chess and video games without physical input, showcasing the transformative potential of the technology.
Expanding frontiers in BCI innovation
Neuralink has been actively expanding its research and clinical trials, demonstrating bold ambitions in brain-computer interface applications.
In a live update earlier this year, Elon Musk outlined a future where Neuralink technology could be used to control advanced robotic limbs, such as the Optimus robotic humanoid, which Tesla debuted in 2022.
“Imagine a scenario where someone who has lost their arms or legs could attach robotic limbs controlled by Neuralink implants,” Musk said.
“Motor commands from the brain could seamlessly operate these robotic limbs, essentially granting individuals cybernetic abilities.”
Global research and recent milestones
Neuralink has made significant strides globally. Recently, the company received approval from Health Canada to conduct the CAN-PRIME Study at Toronto Western Hospital.
This trial will test the N1 implant and R1 robot, which performs precise, robot-assisted brain surgeries.
Neuralink has also achieved FDA breakthrough device designation for its innovative Blindsight implant, designed to restore vision for individuals who are blind.
The Blindsight system uses a microelectrode array implanted into the brain’s visual cortex to activate neurons, creating visual perceptions for the user.
